GlassScriptPhysician profile
Runjhun Bhatia
NPI 1427440718
$2,048.23
in general payments reported to CMS, 2019-2025
29 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $690 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.60 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $195.10 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $154.90 | 2024-2025 | Hyqvia |
| Sk Life Science, INC. | $124.57 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $117.39 | 2025 | Ponvory |
| Pfizer INC. | $106.37 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $86.78 | 2024-2025 | |
| Argenx US, INC. | $81.91 | 2024-2025 | Vyvgart |
| Catalyst Pharmaceuticals, INC. | $74.89 | 2024-2025 | |
| Amgen INC. | $66.88 | 2024-2025 | Uplizna |
| Ucb, INC. | $60.68 | 2024 | Nayzilam, Rystiggo |
| Lundbeck LLC | $54.73 | 2024-2025 | Vyepti |
| Csl Behring | $52.81 | 2024-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $47.95 | 2025 | Nuedexta, Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $47.32 | 2025 | Lumryz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $43.35 | 2025 | |
| Novartis Pharmaceuticals Corporation | $42.67 | 2025 | |
| Alnylam Pharmaceuticals INC. | $36.94 | 2025 | Amvuttra |
| Neurelis, INC. | $31.55 | 2025 | Valtoco |
| Genentech USA, INC. | $31.53 | 2024 | Ocrevus Zunovo, Ocrevus |
| Livanova USA, INC. | $26.56 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $25.99 | 2025 | |
| Cala Health, INC. | $23.90 | 2024 | Cala Kiq, Cala Trio |
| Aucta Pharmaceuticals, INC. | $22.75 | 2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $20.57 | 2025 | Bafiertam |
| Biogen, INC. | $17.76 | 2025 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $14.54 | 2024 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $13.73 | 2025 | Austedo Xr |
| Lilly USA, LLC | $13.51 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Runjhun Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.